What market growth dynamics are being observed in U.S. heart, lung, and liver transplant volumes, and is acceleration occurring?

Waleed Hassanein noted a very strong start to Q3, with July being the highest aviation month. However, he cautioned about August seasonality due to vacations and centers hunkering down. He emphasized the company's focus on driving its own adoption and market share rather than national trends. “We agree we started Q3 very, very strong. In fact, I mean, it's not a secret. It's published on Twitter every day. July was the highest aviation month for the business. But July is not Q3. And we are entering into August, and we all know what happens in August.”

Can you provide an update on the 510(k) pathway for CHOPS and frame its commercial opportunity, including potential indications beyond heart?

Waleed Hassanein stated that the immediate focus is on obtaining IDE approval for the ENHANCE trial, with 510(k) clearance realistically expected in H1 2027. He framed the commercial opportunity for heart at least 2,200 annual U.S. DBD heart cases and hinted that CHOPS could have indications beyond heart, though active discussions with the FDA are ongoing. “As far as the opportunities that it unlocks, as I stated earlier, at least, at least 2,200 annual cases in the U.S. DBD hearts that are done with approximately 4 hours of preservation.”

Can you unpack the new donor and recipient screening services, its potential impact on volume and revenue, and how it benefits customers and TransMedics?

Waleed Hassanein explained that the new service is a natural progression to harmonize the complex and unorganized transplant workflow. By providing streamlined services, technology, and transparency, TransMedics aims to become a trusted partner, supporting centers and driving efficiency. The service is being piloted with a major Boston healthcare system, with the hope of translating into broader adoption and deeper utilization. “We're doing it because we've always stated that the transplant market or the transplant workflow is highly complex and highly unorganized. There's many cooks in the kitchen. And we always believed that harmonizing that workflow into one streamline of services, technology, transparency, accessibility could be a catalyst for what TransMedics is doing.”

TMDX

TransMedics (TMDX) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 4, 2026

Source: earnings call transcript

Executive summary

TransMedics Q2 FY26 — Record Revenue and Strategic Growth Investments

TransMedics delivered record Q2 FY26 revenue, driven by strong OCS case volume and clinical services, particularly in logistics. The company is aggressively investing in four strategic growth initiatives—heart/lung expansion, OCS Kidney development, European market entry, and the next-gen OCS platform—to achieve over $2 billion in annual revenue by 2032, prioritizing long-term growth over near-term operating leverage.

Highlights

Total revenue reached approximately $190 million, marking the highest quarterly revenue in history, up 21% year-over-year and 9% sequentially.
Service revenue grew approximately 29% year-over-year to $79 million, driven by market share gains in logistics and improved operating efficiency.
Adjusted income from operations was approximately $25.8 million, representing a 14% operating margin, while continuing to fund growth initiatives.
The company ended the quarter with approximately $473 million in cash and cash equivalents, providing confidence in self-funding growth investments.
The low end of full-year 2026 revenue guidance was raised to a range of $737 million to $757 million, representing 22% to 25% growth over 2025.

Concerns

Full-year adjusted operating margin guidance (excluding PAD Aviation) was lowered to 12.5% to 14% (from a prior expectation of 16%), reflecting higher planned investment in OCS Kidney.
The initial consolidation of PAD Aviation is expected to be dilutive to both gross margin and operating margin beginning in the third quarter.
ENHANCE Part B and DENOVO clinical programs experienced delays in IDE approval, resulting in minimal contribution to Q2 results.
Total gross margin declined approximately 180 basis points year-over-year, primarily due to a higher mix of service revenue and temporary product cost pressures.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Revenue	$737 million to $757 million high materiality	FY26	High
Full-year 2026 Adjusted Operating Margin (excluding PAD Aviation)	approximately 12.5% to 14% high materiality	FY26	Medium
Full-year 2026 Gross Margin (excluding PAD Aviation)	approximately 59% medium materiality	H2 FY26	Medium
Long-term Gross Margin	approximately 60% medium materiality	Long-term	Medium
Transplants Supported by TransMedics Platform	approximately 30,000 high materiality	by 2032 · FY32	High
Annual Revenue	more than $2 billion high materiality	by 2032 · FY32	High
OCS Kidney First Clinical Experience	later in 2027 high materiality	CY27 · FY27	Medium
Italy National Reimbursement for Machine Perfusion and Services	take effect later this year or early 2027 medium materiality	H2 CY26 or H1 CY27	Medium
ENHANCE Part B IDE Supplement Approval	late Q3 or early fourth quarter high materiality	Q3 FY26	Medium
Lung IDE Approval	shortly thereafter medium materiality	Q4 FY26	Medium
ENHANCE Part A Completion	before year-end medium materiality	FY26	High
Full-year 2026 Headquarter-related Interest Expense	$15.3 million low materiality	FY26	High
Full-year 2026 Total Interest Expense	approximately $29 million low materiality	FY26	High
Full-year 2026 Interest Income	approximately $12 million low materiality	FY26	High
Full-year 2026 Effective Tax Rate	approximately 26% low materiality	FY26	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Total Company Highest quarterly revenue in company history.	$190M	21%	9%	—
U.S. Transplant Strong growth across OCS case volume and clinical services.	$184M	21%	10%	—
International Reflects continued progress in expanding European presence; early innings of growth story with expected quarterly variability.	$5M	26%	—	—
Transplant Product Growth led by liver.	$111M	16%	3%	—
Service Increase primarily driven by broader adoption of TransMedics Logistics and pricing adjustments. Service margin improved from 27% in Q1 FY26 to 35% in Q2 FY26 due to higher fleet utilization, improved operating efficiency, and optimization. Service revenue as % of total revenue: 41%	$79M	29%	19%	35%
Liver Led overall growth.	$148M	28%	7%	—
Heart Expected to accelerate in Q4 and beyond with ENHANCE Part B.	$33M	6%	23%	—
Lung Minimal contribution from DENOVO clinical program.	$2M	—	—	—
TransMedics Logistics Clear evidence of vertical integration as a growth engine and structural differentiator. Improved operating efficiency. NOP mission requiring air transport coverage: 86% (up from 82% in Q1)	$41M	39%	30%	—

Product announcements

Product	Type	Timeline	Details
Donor and Recipient Clinical Screening Coordination Services	launch	Effective July 1, 2026

Deals & partnerships

PAD Aviation Strategic investment to establish TransMedics Aviation Europe and build a pan-European transplant logistics network.

PAD Aviation is located in Paderborn, Germany, providing a central location for accessing European countries. The acquisition provides the license to operate in Europe, access to a large number of pilots, and a sizable fleet. The plan is to transition PAD's existing third-party charter business into 100% transplant operations over time as demand ramps up.

Risks & headwinds

Operating margin dilution from strategic investments FY26

Full-year 2026 adjusted operating margin guidance lowered to 12.5% to 14% (from 16%)

Mitigation:Deliberate acceleration of key strategic growth programs (e.g., OCS Kidney) for long-term value creation, not broad-based overhead expansion.

Dilutive impact from PAD Aviation acquisition Beginning Q3 FY26

Initial consolidation will be dilutive to both gross margin and operating margin

Mitigation:Expects financial profile to improve over time as the business is integrated and utilization for transplant missions increases.

Delays in clinical trial approvals Q2 FY26, ongoing

Minimal contribution from ENHANCE Part B or DENOVO clinical programs in Q2

Mitigation:Working collaboratively with FDA; IDE supplement for ENHANCE Part B expected late Q3/early Q4, Lung IDE to follow shortly. Focus on rapid adoption post-approval.

Gross margin pressure Q2 FY26

Down approximately 180 basis points year-over-year

Mitigation:Primarily reflects higher mix of service revenue and temporary product cost pressures (inventory provisioning, trial-related solution costs), partially offset by improved logistics performance and operating efficiencies. Expects some normalization in service margin in H2.

Seasonal softness in transplant procedure volume Q3 FY26

Q3 is traditionally a seasonally soft quarter

Mitigation:Acknowledged by management, with caution regarding August trends. Company focuses on driving its own adoption and market share.

What to watch in Q3 FY26

ENHANCE Part B IDE Supplement Approval

late Q3 or early Q4

Current Under FDA review

Target Approval by late Q3 or early Q4

Why it matters

This approval is critical for unlocking the ENHANCE Part B trial, which targets a significant U.S. heart segment and is a key driver for future growth.

We expect it to be approved by late Q3 or early fourth quarter, with the lung IDE to follow shortly thereafter.

Find out whether TMDX delivers this. Inve re-checks your case every morning.

Q&A highlights

What drove the strong increase in service revenues, outpacing disposables, and were dry runs a factor?

Waleed Hassanein clarified that there was no increase in dry run rates. He attributed the service revenue growth to gaining market share in logistics, improved operating efficiency, pricing adjustments to offset higher costs, and the addition of new centers.

“Gaining market share in logistics, gaining a lot of efficiency in our logistics, improving our margins, pricing adjustment to buffer against the increase in costs, new centers. So that's -- these all combined lead to that picture.”

asked by K. Gong · answered by Waleed Hassanein

2 min read 6 chapters

Detailed narrative

Strategic Platform and Moat

TransMedics has developed a first-in-class, vertically integrated organ transplant platform comprising four distinct assets: the Organ Care System (OCS) technology, the National OCS Program (NOP), the Transplant Logistics Network, and the NOP Connect digital ecosystem. These assets, which required significant time and capital to build, create a substantial competitive moat. The company is committed to continuously widening this moat through ongoing innovation and strategic investments.

New Service Offering for Workflow Efficiency

Effective July 1, 2026, TransMedics launched a new service offering: donor and recipient clinical screening coordination services. This service aims to enable transplant programs to run more of their workflow efficiently on the TransMedics platform. The company is piloting this initiative with a major healthcare system in Boston, expecting it to streamline processes, enhance support for centers, and provide greater visibility into the national donor pool, ultimately driving more transplants.

Massive Kidney Transplant Opportunity

The U.S. kidney transplant market presents a massive opportunity, with over 21,000 deceased kidney transplants annually and approximately 9,200 recovered kidneys in 2024 that were never transplanted due to cold storage limitations. OCS Kidney, currently under development on the next-gen Gen 3.0 platform, is designed to be the first portable normothermic oxygenated perfusion system to significantly reduce ischemia and reperfusion injury.

It also aims to include online functional assessment capabilities, with the potential to increase donor kidney utilization and reduce delayed graft function (DGF), which affects 26-50% of recipients and incurs significant costs.

European Expansion and PAD Aviation Investment

TransMedics is actively replicating its successful U.S. NOP and logistics model in Europe, beginning with Italy, where national reimbursement for machine perfusion and services is anticipated to take effect in late 2026 or early 2027. The strategic investment in PAD Aviation in Germany, closed on July 1, 2026, is a crucial step, providing the necessary aviation infrastructure and license to compete for transplant logistics tenders across Italy and other European countries.

This expansion leverages existing capabilities to materially grow the addressable market and extend life-saving impact.

Next-Generation OCS Platform (Gen 3.0)

The OCS Gen 3.0 platform represents a complete redesign of the OCS system, engineered to deliver significant operating leverage and supply chain independence. This next-gen platform is designed to be highly autonomous, incorporating cloud-based remote monitoring and control capabilities. Its development is critical for scaling clinical usage and supporting an operating capacity of 30,000 transplants and beyond globally by 2032, providing a foundation for future growth.

Growth-Oriented Capital Allocation

TransMedics maintains a clear capital allocation priority focused on durable top-line growth ahead of near-term operating leverage. The company is funding four key growth initiatives—heart and lung expansion (ENHANCE/DENOVO), OCS Kidney development, international expansion, and the NextGen OCS platform—over the next 18 to 24 months.

Management emphasizes its track record of outperforming growth expectations and delivering strong bottom-line performance, asserting that these investments are crucial for achieving over $2 billion in annual revenue by 2032.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.